14-day Premium Trial Subscription Sign Up For FreeGet Free

Aclaris Therapeutics Stock News NASDAQ:ACRS

WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the Settlement Hearing) will be held on November 30, 2021 at 11:00 a.m. ET, before the Honorable Lewis J. Liman at the U.S. District Court for the Southern District of New York, 500 Pearl Street, New York, NY 10007 (the Court) in the matter of In re Aclaris Therapeutics, Inc. Derivative Litigation , Lead Case No. 1:19-cv-10641-LJL (the Consolidated Derivative Action). Read more

Aclaris Therapeutics EPS misses by $0.06, beats on revenue

11:53am, Thursday, 05'th Aug 2021 Seeking Alpha
Read more
WAYNE, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2021 and provided a corporate update. Read more
Hair loss can be caused by numerous disorders. Alopecia areata or hair loss begins after the onset of puberty. Alopecia is a common autoimmune disorder that often results in unpredictable hair loss on the scalp, face, and other areas of Read more
Los Angeles, July 14, 2021 (GLOBE NEWSWIRE) -- Hidradenitis Suppurativa Pipeline Landscape: Novel Emerging Therapies and Key Pharmaceutical Companies Reinvigorates the Pipeline Landscape The Hidradenitis Suppurativa pipeline landscape includes several therapies with different mechanisms of action currently being studied with great market potential. Ongoing scientific research has provided greater sophistication and a clearer understanding of the mechanisms of therapeutic interventions for Hidradenitis suppurativa. DelveInsight''s '' Hidradenitis Suppurativa Pipeline Insights '' report presents an exhaustive coverage of the available therapies, Hidradenitis Suppurativa emerging drug therapies in different phases of clinical development, key companies working to advance the Hidradenitis Suppurativa pipeline therapies, and the future market scope of the space. Some of the notable pointers extracted from the Hidradenitis Suppurativa (HS) Pipeline report: DelveInsight''s analysis depicts a robust Hidradenitis Suppurativa Pipeline with 25+ active players in the domain working on 25+ pipeline therapies. Read more
WAYNE, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a virtual panel discussion at the William Blair Biotech Focus Conference 2021 titled Novel Targets for Autoimmune Diseases, on Thursday, July 15, 2021 at 11:00 a.m. ET. Management will be available July 15th throughout the day for virtual one-on-one meetings. Read more

Aclaris Therapeutics (ACRS) Gets a Buy Rating from H.C. Wainwright

10:25am, Wednesday, 16'th Jun 2021 Smarter Analyst
In a report released today, Ram Selvaraju from H.C. The post Aclaris Therapeutics (ACRS) Gets a Buy Rating from H.C. Wainwright appeared first on Smarter Analyst . Read more
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Chinook Therapeutics (KDNY), Aclaris Therapeutics The post Analysts Offer Insights on Healthcare Companies: Chinook Therapeutics (KDNY), Aclaris Therapeutics (ACRS) and Translate Bio (TBIO) appeared first on Smarter Analyst . Read more

Aclaris Therapeutics prices $125M public stock offering

02:51pm, Thursday, 10'th Jun 2021 Business Journals
The company said it may use a portion of the net proceeds to invest in or acquire additional businesses or technologies. Read more
The global Hair Loss Treatment market which projected a CAGR of approximately +7% in the midst of the estimate time span of 2020-2027. Coherent Market Insights has added a new report to its database that qualifies an expressive and professional look Read more

Aclaris Therapeutics secures $125M capital via equity raise

04:29am, Thursday, 10'th Jun 2021 Seeking Alpha
Read more

Aclaris Announces Pricing of Public Offering of Common Stock

11:55pm, Wednesday, 09'th Jun 2021 Intrado Digital Media
WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,042,254 shares of its common stock at a price to the public of $17.75 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 1,056,338 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters option. The offering is expected to close on or about June 14, 2021, subject to customary closing conditions. Read more

Aclaris to meet competition from Incyte in atopic dermatitis

05:46pm, Wednesday, 09'th Jun 2021 Seeking Alpha
Read more

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE